ReviewCancer medicine2026
Efficacy and Safety of First-Line Treatment Options for Oncogene Wild-Type Lung Adenocarcinoma With Liver Metastases.
Review in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveLiver metastasis represents one of the frequent drivers for cancer-related mortality in lung adenocarcinoma. For advanced lung adenocarcinoma harboring wild-type oncogene drivers, chemotherapies in combination with immune checkpoint inhibitors (ICIs) and/or bevacizumab (named IC, BC, and IBC, respectively) are alternative first-line schemes as recommended by canonical treatment guidelines. However, due to the immunosuppressive tumor microenvironment in the liver, patients with liver metastases are less effective to ICIs. For this subpopulation, the optimal regimen is still undetermined.
methodsIn this retrospective multicenter cohort study, treatment-naïve lung adenocarcinoma patients with wild-type oncogene drivers and liver metastases were enrolled from 4 cancer centers between January 2018 and December 2023. All these patients received BC, IC, or IBC as the first-line therapies. Propensity Score Matching (PSM) was applied to balance baseline covariates. Kaplan-Meier survival analysis, log-rank tests, and Cox proportional-hazards regression were used to compare PFS and OS among groups.
resultsA total of 191 Patients were enrolled, in which 70 (36.6%) received IC treatment, 70 (36.6%) received BC and 51 (26.7%) received IBC treatment. After PSM, 135 eligible patients were selected, including 45 Patients in each group. IBC group showed a slightly higher ORR (44.4%) and significantly higher DCR (95.6%, p = 0.013) compared with BC (ORR = 37.2%, DCR = 81.4%) and IC (ORR = 38.5%, DCR = 71.8%) groups, as evaluated by the primary lung lesions. When liver metastases were used as target lesions, similar response was observed. The median progression-free survival (mPFS) in patients receiving IBC (8.48 months, 95% CI: 5.98-16.10 months) was significantly longer than those receiving BC (5.09 months, 95% CI: 3.55-7.46 months) and IC (4.86 months, 95% CI: 3.06-7.82 months) (IBC vs. BC: HR = 0.477, 95% CI: 0.295-0.772, p = 0.002; IBC vs. IC: HR = 0.479, 95% CI: 0.292-0.784, p = 0.003). IBC also showed a numerically longer OS than IC (18.99 months vs. 12.52 months; HR = 0.692, 95% CI: 0.429-1.114, p = 0.128), although this difference did not reach statistical significance. Subgroup analyses, conducted as pre-specified exploratory analyses, showed that patients with male gender, smoking history, brain metastasis, polymetastases and low PD-L1 expression (< 50%) displayed superior PFS when treated with IBC compared with their counterparts. Besides, IBC showed comparable adverse events relative to IC and BC treatments.
conclusionsIBC treatment showed superior efficacy in oncogene wild-type lung adenocarcinoma patients with liver metastases, especially in those with male gender, smoking history, brain metastasis, polymetastases, and low PD-L1 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.